Rarity Bioscience
Rarity Bioscience is dedicated to radically improving mutation detection through its ultrasensitive superRCA® technology. Founded in 2021 as a spin-out from Uppsala University, the company focuses on developing and commercializing assays for research and clinical applications, particularly in liquid biopsy and cancer diagnostics. With a mission to enable the full potential of liquid biopsies, Rarity Bioscience offers ultra-sensitive, multiplex, fast, and cost-efficient mutation detection solutions, aiming to enhance early cancer detection, diagnosis, and treatment.
Industries
Nr. of Employees
small (1-50)
Rarity Bioscience
Dag Hammarskjölds Väg 56E, 752 37 Uppsala, Sweden
Products
NPM1 mutation detection kit (RUO)
Research-use kit for detection of NPM1 mutations in DNA samples intended for research applications such as MRD monitoring.
Acute myeloid leukemia (AML) mutation panel (research service)
Panel covering relevant AML-associated mutations offered for research service testing to support targeted treatment decision studies and MRD monitoring.
NPM1 mutation detection kit (RUO)
Research-use kit for detection of NPM1 mutations in DNA samples intended for research applications such as MRD monitoring.
Acute myeloid leukemia (AML) mutation panel (research service)
Panel covering relevant AML-associated mutations offered for research service testing to support targeted treatment decision studies and MRD monitoring.
Services
Laboratory-based service testing for detection of low-frequency DNA mutations in tissue and liquid biopsy samples, with multiplex capability and flow cytometer read-out.
Custom design and production of research-use assay panels and kits tailored to specified mutation targets and study needs.
Quantification service for integrated retroviral vector copy number in engineered T-cells intended to support translational and cell therapy studies.
Laboratory-based service testing for detection of low-frequency DNA mutations in tissue and liquid biopsy samples, with multiplex capability and flow cytometer read-out.
Custom design and production of research-use assay panels and kits tailored to specified mutation targets and study needs.
Quantification service for integrated retroviral vector copy number in engineered T-cells intended to support translational and cell therapy studies.
Expertise Areas
- Minimal residual disease (MRD) monitoring
- Liquid biopsy diagnostics
- Multiplexed molecular assay development
- Flow cytometry-based molecular readouts
Key Technologies
- Rolling circle amplification with secondary amplification
- High-plex multiplexed nucleic acid detection
- Flow cytometry read-out for molecular assays
- Ultra-low allele-fraction mutation detection
News & Updates
Dr. Andrea Ballagi joins the board of Rarity Bioscience, bringing extensive expertise.
Collaboration to enhance mutation detection capabilities.
Funding to expand operations and product development within precision diagnostics and liquid biopsy.
The superRCA technology can detect residual cancer cells after treatment of AML with greater sensitivity than PCR-based technologies.
Dr. Lei Chen awarded for significant efforts and progress from idea to innovation.
Supporting analysis of vector copy number in engineered T-cells for CAR-T therapy.
Dr. Andrea Ballagi joins the board of Rarity Bioscience, bringing extensive expertise.
Collaboration to enhance mutation detection capabilities.
Funding to expand operations and product development within precision diagnostics and liquid biopsy.
The superRCA technology can detect residual cancer cells after treatment of AML with greater sensitivity than PCR-based technologies.
Dr. Lei Chen awarded for significant efforts and progress from idea to innovation.
Supporting analysis of vector copy number in engineered T-cells for CAR-T therapy.